Article: FDA Grants Approval to Market FOCALIN XR(TM) for the Treatment of ADHD in Adults, Adolescents and Children.

SUMMIT, N.J., May 27 /PRNewswire-FirstCall/ -- Celgene Corporation announced that Novartis Pharma AG, its partner in the development and commercialization of FOCALIN XR, was granted U.S. Food and Drug Administration (FDA) approval for FOCALIN XR (dexmethylphenidate HCl) extended-release capsules for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults, adolescents and children. The approval of FOCALIN XR for the treatment of ADHD was based on efficacy and safety data from clinical trials involving approximately 320 adults, adolescents and children diagnosed with ADHD.

"FOCALIN XR provides a new treatment option for adults, adolescents and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!